Compounds > salvigenin
Page last updated: 2024-12-08

salvigenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

salvigenin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

salvigenin : A trimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4', 6, and 7 are replaced by methoxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID161271
CHEMBL ID376644
CHEBI ID192703
SCHEMBL ID1427018
MeSH IDM0062286

Synonyms (32)

Synonym
5-hydroxy-6,7,4'-trimethoxyflavone
salvigenin
CHEMBL376644
LMPK12111166
psathyrotin
5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)-4h-chromen-4-one
7-o-methylpectolinarigenin
CHEBI:192703
5-hydroxy-4',6,7-trimethoxyflavone
5-hydroxy-6,7,4'-trimethoxy-flavone
5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)-4h-1-benzopyran-4-one
19103-54-9
5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one
v522ycm28a ,
4h-1-benzopyran-4-one, 5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)-
unii-v522ycm28a
bdbm50092613
SCHEMBL1427018
4h-1-bbenzopyran-4-one, 5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)-
flavone, 5-hydroxy-4',6,7-trimethoxy-
QCDYOIZVELGOLZ-UHFFFAOYSA-N
DTXSID90172629 ,
J-012342
salvesigenine
AKOS032948589
HY-N1318
Q63398893
FT-0775503
CS-0016722
MS-24914
dtxcid0095120
B0005-172412

Research Excerpts

Overview

Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutelliariae Radix. It is demonstrated to have anti-tumor properties in colon cancer.

ExcerptReferenceRelevance
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer. "( Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.
Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023)		3.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
autophagy inducerAny compound that induces the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
immunomodulatorBiologically active substance whose activity affects or plays a role in the functioning of the immune system.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
hypoglycemic agentA drug which lowers the blood glucose level.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
trimethoxyflavoneA methoxyflavone that is flavone substituted by three methoxy groups.
monohydroxyflavoneA hydroxyflavone carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
nevadensin biosynthesis012
salvigenin biosynthesis713
nevadensin biosynthesis013

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)IC50 (µMol)0.47330.00010.32759.5480AID1756088; AID1756090; AID1756091
Delta-type opioid receptorHomo sapiens (human)Ki26.00000.00000.59789.9300AID1230327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (44)

Processvia Protein(s)Taxonomy
hemopoiesisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
leukocyte homeostasisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
myeloid progenitor cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
pro-B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of cell population proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
response to organonitrogen compoundReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
animal organ regenerationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
common myeloid progenitor cell proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of apoptotic processReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAP kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
lymphocyte proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein autophosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to cytokine stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to glucocorticoid stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
dendritic cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
multicellular organism developmentReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
ATP bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
nuclear glucocorticoid receptor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
phosphatidylinositol 3-kinase activator activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
growth factor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
endoplasmic reticulumReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endoplasmic reticulum lumenReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endosome membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
receptor complexReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1756116Cell cycle arrest in human MV4-11 cells assessed as accumulation at S phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 17.51 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756092Cytotoxicity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756109Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G2/M phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 20.36 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1265076Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of prothrombin time at 100 uM after 3 mins (Rvb = 4.99 +/- 0.18 seconds)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1070435Activation of Nrf2 (unknown origin) expressed in CHO-ARE luc cells at 10 to 30 uM after 18 hrs by luciferase reporter gene assay2014Journal of natural products, Mar-28, Volume: 77, Issue:3
Identification of chromomoric acid C-I as an Nrf2 activator in Chromolaena odorata.
AID1265075Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of thrombin time at 100 uM after 3 mins (Rvb = 20.25 +/- 1.02 seconds)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1230327Displacement of [3H]DPDPE from delta opioid receptor (unknown origin) transfected into HEK293 cells by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID1756108Cell cycle arrest in human MOLM-13 cells assessed as accumulation at S phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 11.14 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1230329Displacement of [3H]-CP55940 from human CB2 receptor transfected into HEK293 cells at 10 uM by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID1756119Cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 50.06 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756091Inhibition of recombinant His-tagged human FLT3 D835Y mutant (564 to 958 residues) expressed in baculovirus expression system using tyr 02 as substrate incubated for 1 hr by Z'-LYTE assay2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756090Inhibition of recombinant N-terminal GST/His6-tagged human FLT3 ITD mutant (571 to 993 residues) expressed in Sf9 insect cells incubated for 1 hr by LanthaScreen assay2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756111Cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 50.06 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1265084N-octanol/0.15 M NaCl partition coefficient, log P of the compound after 5 hrs by spectrophotometric analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1230328Displacement of [3H]-CP55940 from human CB1 receptor transfected into HEK293 cells at 10 uM by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID280040Cytotoxicity against human HUVEC cells2007Journal of natural products, Mar, Volume: 70, Issue:3
Cytotoxic constituents from the fruiting branches of Callicarpa americana collected in southern Florida.
AID1756121Cell cycle arrest in human MV4-11 cells assessed as accumulation at G2/M phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 26.26 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID280039Cytotoxicity against human TERT-RPE1 cells2007Journal of natural products, Mar, Volume: 70, Issue:3
Cytotoxic constituents from the fruiting branches of Callicarpa americana collected in southern Florida.
AID1265083N-octanol/0.1 M HCl partition coefficient, log P of the compound after 5 hrs by spectrophotometric analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1756123Cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 50.06 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756093Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1265081Antioxidant activity in rat PC12 cells assessed as inhibition of H2O2-induced cytotoxicity at 25 uM after 4 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1756128Cell cycle arrest in human MV4-11 cells assessed as increase in accumulation at sub-G1 phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756125Cell cycle arrest in human MV4-11 cells assessed as accumulation at G2/M phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 26.26 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756089Inhibition of recombinant His-tagged human FLT3 (564 to 958 residues) expressed in baculovirus expression system at 10 uM using tyr 02 as substrate incubated for 1 hr by Z'-LYTE assay relative to control2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756127Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G0/G1 phase at 0.3 to 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756112Cell cycle arrest in human MV4-11 cells assessed as accumulation at S phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 17.51 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1265085N-octanol/0.15 M NaHCO3 partition coefficient, log P of the compound after 5 hrs by spectrophotometric analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1265079Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1265082Aqueous solubility of the compound in water after 1 hr by UV-vis spectrophotometer analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1756122Cell cycle arrest in human MV4-11 cells assessed as accumulation at sub-G1 phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 7.43 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756115Cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 50.06 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1230324Displacement of [3H]DPDPE from delta opioid receptor (unknown origin) transfected into HEK293 cells at 10 uM by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID1230325Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) transfected into HEK293 cells at 10 uM by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID1756100Cell cycle arrest in human MOLM-13 cells assessed as accumulation at S phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 11.14 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756088Inhibition of recombinant His-tagged human FLT3 (564 to 958 residues) expressed in baculovirus expression system using tyr 02 as substrate incubated for 1 hr by Z'-LYTE assay2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1265080Antioxidant activity in rat PC12 cells assessed as inhibition of H2O2-induced cytotoxicity at 50 uM after 4 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1756113Cell cycle arrest in human MV4-11 cells assessed as accumulation at G2/M phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 26.26 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756117Cell cycle arrest in human MV4-11 cells assessed as accumulation at G2/M phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 26.26 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756118Cell cycle arrest in human MV4-11 cells assessed as accumulation at sub-G1 phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 7.43 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756124Cell cycle arrest in human MV4-11 cells assessed as accumulation at S phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 17.51 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID280038Cytotoxicity against human LNCaP cells2007Journal of natural products, Mar, Volume: 70, Issue:3
Cytotoxic constituents from the fruiting branches of Callicarpa americana collected in southern Florida.
AID1756101Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G2/M phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 20.36 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756104Cell cycle arrest in human MOLM-13 cells assessed as accumulation at S phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 11.14 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID280036Cytotoxicity against human Lu1 cells2007Journal of natural products, Mar, Volume: 70, Issue:3
Cytotoxic constituents from the fruiting branches of Callicarpa americana collected in southern Florida.
AID280037Cytotoxicity against human Col2 cells2007Journal of natural products, Mar, Volume: 70, Issue:3
Cytotoxic constituents from the fruiting branches of Callicarpa americana collected in southern Florida.
AID1756102Cell cycle arrest in human MOLM-13 cells assessed as accumulation at sub-G1 phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 13.76 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756103Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G0/G1 phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 53.92 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756120Cell cycle arrest in human MV4-11 cells assessed as accumulation at S phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 17.51 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1265078Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of fibrinogen at 100 uM after 3 mins (Rvb = 7.02+/- 0.16 g/L)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1756099Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G0/G1 phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 53.92 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1230330Agonist activity at human delta opioid receptor transfected into HEK293 cells assessed as effect on [35S]-GTPgammaS binding at 300 uM2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID1756096Cell cycle arrest in human MOLM-13 cells assessed as accumulation at S phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 11.14 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756114Cell cycle arrest in human MV4-11 cells assessed as accumulation at sub-G1 phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 7.43 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756097Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G2/M phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 20.36 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756105Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G2/M phase at 10 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 20.36 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID280035Cytotoxicity against human MCF7 cells2007Journal of natural products, Mar, Volume: 70, Issue:3
Cytotoxic constituents from the fruiting branches of Callicarpa americana collected in southern Florida.
AID1265077Antithrombotic activity in New Zealand white rabbit platelet-poor plasma assessed as increase of activated partial thromboplastin time at 100 uM after 3 mins (Rvb = 30.58 +/- 1.55 seconds)2015European journal of medicinal chemistry, Dec-01, Volume: 106Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo.
AID1756110Cell cycle arrest in human MV4-11 cells assessed as accumulation at sub-G1 phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 7.43 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756095Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G0/G1 phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 53.92 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756098Cell cycle arrest in human MOLM-13 cells assessed as accumulation at sub-G1 phase at 3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 13.76 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756107Cell cycle arrest in human MOLM-13 cells assessed as accumulation at G0/G1 phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 53.92 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756094Cell cycle arrest in human MOLM-13 cells assessed as accumulation at sub-G1 phase at 0.3 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 13.76 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
AID1756106Cell cycle arrest in human MOLM-13 cells assessed as accumulation at sub-G1 phase at 30 uM measured after 72 hrs by propidium iodide/RNaseA staining based flow cytometry analysis (Rvb = 13.76 %)2021Journal of natural products, 01-22, Volume: 84, Issue:1
Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (12.50)29.6817
2010's18 (75.00)24.3611
2020's3 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.47 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.610nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
propane
Propane: A three carbon alkane with the formula H3CCH2CH3.		2.0810alkane;
gas molecular entity		food propellant
methylene chloride
Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.		2.0810chloromethanes;
volatile organic compound		carcinogenic agent;
polar aprotic solvent;
refrigerant
2-methylpentane
Hexanes: Six-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives. Various polyneuropathies are caused by hexane poisoning.		2.1510alkane
n-hexane
hexane : An unbranched alkane containing six carbon atoms.		2.1510alkane;
volatile organic compound		neurotoxin;
non-polar solvent
oleanolic acid
[no description available]		2.8130hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
flavone
flavone: RN given refers to unlabeled cpd; structure given in first source. flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2.		2.110flavonesmetabolite;
nematicide
hesperetin
[no description available]		2.1103'-hydroxyflavanones;
4'-methoxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone		antineoplastic agent;
antioxidant;
plant metabolite
Tormentic acid
tormentic acid: aglycone of Rosamultin		2.2510triterpenoidmetabolite
xanthomicrol
xanthomicrol: structure in first source. xanthomicrol : A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 8 and hydroxy groups at positions 5 and 4'.		2.1110dihydroxyflavone;
trimethoxyflavone		antineoplastic agent;
plant metabolite
taxodione
taxodione: structure		2.0710diterpenoid
umuhengerin
umuhengerin: isolated from Lantana trifolia; structure given in first source		2.0510
4',5,6,7-tetramethoxyflavone
4',5,6,7-tetramethoxyflavone: structure given in first source; from plant Eupatorium odoratum. 4',5,6,7-tetramethoxyflavone : A tetramethoxyflavone that is the tetra-O-methyl derivative of scutellarein.		2.110tetramethoxyflavoneantimutagen;
plant metabolite
eupatorin
eupatorin: a flavonoid from the East Asian medicinal plant Orthosiphon spicatus; prevents oxidative inactivation of 15-lipoxygenase; structure given in first source. eupatorin : A trimethoxyflavone that is 6-hydroxyluteolin in which the phenolic hydogens at positions 4', 6 and 7 have been replaced by methyl groups.		2.8330dihydroxyflavone;
polyphenol;
trimethoxyflavone		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent
loliolide
loliolide: RN given refers to (6S-cis)-isomer		2.0610benzofuransmetabolite
cp-55,940
[no description available]		2.1110
5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone
5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone: has antineoplastic activity; structure in first source		2.0510ether;
flavonoids
sinensetin
sinensetin: isolated from citrus fruit; exhibit antiadhesive action on platelets. sinensetin : A pentamethoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 3' and 4' respectively.		2.2110pentamethoxyflavoneplant metabolite
5-hydroxy-3',4',6,7-tetramethoxyflavone
5-hydroxy-3',4',6,7-tetramethoxyflavone: isolated from Artemisia argyi		2.1110
cirsiliol
cirsiliol: potent inhibitor of arachidonate lipooxygenase. cirsiliol : A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5, 3' and 4' respectively.		2.0510dimethoxyflavone;
trihydroxyflavone		plant metabolite
nevadensin
nevadensin: from Lysionotus pauceflora Maxim; RN & N1 from 9th CI. nevadensin : A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 8 and 4' and hydroxy groups at positions 5 and 7 respectively.		7.1110dihydroxyflavone;
trimethoxyflavone		plant metabolite
cirsilineol
cirsilineol: isolated from Thymus carnosus Boiss.. cirsilineol : A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 3' and hydroxy groups at positions 5 and 4' respectively.		2.6320dihydroxyflavone;
trimethoxyflavone		antineoplastic agent;
plant metabolite
sclareol
sclareol: structure given in first source. sclareol : A labdane diterpenoid that is labd-14-ene substituted by hydroxy groups at positions 8 and 13. It has been isolated from Salvia sclarea.		2.5220labdane diterpenoidantifungal agent;
antimicrobial agent;
apoptosis inducer;
fragrance;
plant metabolite
scutellarin
scutellarin: see scutellarein for aglycone. scutellarin : The glycosyloxyflavone which is the 7-O-glucuronide of scutellarein.		2.1110glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor
cirsimaritin
cirsimaritin: has antagonist or partial agonist activity on benzodiazepine receptors. cirsimaritin : A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5 and 4' respectively.		3.1850dihydroxyflavone;
dimethoxyflavone
sorafenib
[no description available]		2.3110(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.0610
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.110(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
nitroarginine
Nitroarginine: An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6). N(gamma)-nitro-L-arginine : An L-arginine derivative that is L-arginine in which the terminal nitrogen of the guanidyl group is replaced by a nitro group.		2.0210guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
carnosol
carnosol: isolated from Lepechinia hastata		2.1510diterpenoid
gamma-sitosterol
clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.		2.51203beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite
euscaphic acid
euscaphic acid: isolated from medicinal plant, Euscaphis japonica Pax.; structure; RN given refers to 2alpha,3alpha-isomer. euscaphic acid : A pentacyclic triterpenoid that is urs-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 19 respectively (the 2alpha,3alpha-stereoisomer). It has been isolated from the leaves of Rosa laevigata.		2.4620hydroxy monocarboxylic acid;
pentacyclic triterpenoid;
triol		plant metabolite
ladanein
ladanein: from Marrubium peregrinum; structure in first source. ladanein : A dimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4' and 7 are replaced by methoxy groups. It is an effective anti-HCV agent.		2.830dihydroxyflavone;
dimethoxyflavone		antiviral agent;
plant metabolite;
radical scavenger
cytellin
cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982		2.5120
eupatilin
eupatilin: isolated from Artemisia argyi. eupatilin : A trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities.		2.5520dihydroxyflavone;
trimethoxyflavone		anti-inflammatory agent;
anti-ulcer drug;
antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
metabolite
acacetin
5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.		2.5720dihydroxyflavone;
monomethoxyflavone		anticonvulsant;
plant metabolite
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		2.4520trihydroxyflavoneantineoplastic agent;
metabolite
luteolin
[no description available]		2.02103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
kaempferol
[no description available]		2.1107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
apigenin dimethylether
apigenin dimethylether: a dimethoxy analog of apigenin from roots of Rhus undulata and possibly other plants. apigenin 7,4'-dimethyl ether : A dimethoxyflavone that is the 7,4'-dimethyl ether derivative of apigenin.		2.7330dimethoxyflavone;
monohydroxyflavone		plant metabolite
genkwanin
genkwanin: structure. genkwanin : A monomethoxyflavone that is apigenin in which the hydroxy group at position 7 is methylated.		2.7630dihydroxyflavone;
monomethoxyflavone		metabolite
hispidulin
hispidulin : A monomethoxyflavone that is scutellarein methylated at position 6.		2.5820monomethoxyflavone;
trihydroxyflavone		anti-inflammatory agent;
anticonvulsant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite
6-hydroxyluteolin
6-hydroxyluteolin: isolated from Thymus carnosus Boiss.. 6-hydroxyluteolin : A pentahydroxyflavone that is luteolin with an additional hydroxy group at position 6.		2.0210pentahydroxyflavone
kaempferide
kaempferide: structure in first source. kaempferide : A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.		2.1107-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite
scutellarein
scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.		2.1110tetrahydroxyflavonemetabolite
tricin
tricin: from Spartina cynosuroides and other plants; structure		2.25103'-methoxyflavones;
dimethoxyflavone;
trihydroxyflavone		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite
naloxone
Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.		2.1110morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
15-deoxy-delta(12,14)-prostaglandin j2
15-deoxy-delta(12,14)-prostaglandin J2: 15-deoxy-PGJ2 is also available; check for double bonds (indicated by delta) at 12 and 14 positions. 15-deoxy-Delta(12,14)-prostaglandin J2 : A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions.		2.110prostaglandins Jelectrophilic reagent;
insulin-sensitizing drug;
metabolite
ombuine
ombuine: from rhizome of Alpinia tonkinensis. ombuin : A dimethoxyflavone that is quercetin in which the hydroxy groups at positions 7 and 4' are replaced by methoxy groups. Isolated from Cyperus teneriffae, it exhibits anti-inflammatory activity.		2.110dimethoxyflavone;
flavonols;
trihydroxyflavone		anti-inflammatory agent;
plant metabolite
5,7-dihydroxy-4',6-dimethoxyflavone
5,7-dihydroxy-4',6-dimethoxyflavone: from Cirsium japonicum D. C.. pectolinarigenin : A dimethoxyflavone that is the 6,4'-dimethyl ether derivative of scutellarein.		3.0540dihydroxyflavone;
dimethoxyflavone		plant metabolite
beta-escin
[no description available]		2.0810
rosmanol
rosmanol: structure in first source		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4720
Innate Inflammatory Response
[description not available]		02.110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.110
Acute Myelogenous Leukemia
[description not available]		02.3110
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.3110
Hepatocellular Carcinoma
[description not available]		07.610
Cancer of Liver
[description not available]		02.610
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.610
Liver Neoplasms
Tumors or cancer of the LIVER.		02.610
Alloxan Diabetes
[description not available]		02.2110
Ache
[description not available]		02.1110
Anxiety
Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.		02.1110
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		02.1110
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.1110
Breast Cancer
[description not available]		02.1510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1510
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0510
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		02.0710
Muscle Relaxation
That phase of a muscle twitch during which a muscle returns to a resting position.		02.0210
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.0210